Can Norepinephrine (Levophed) Be Used in Pulmonary Hypertension?
Yes, norepinephrine can be used in patients with pulmonary hypertension, particularly when systemic hypotension and right ventricular failure are present, as it preferentially increases systemic vascular resistance while maintaining or even improving pulmonary hemodynamics.
Rationale and Evidence
The key to understanding norepinephrine use in PH lies in recognizing that systemic hypotension with right ventricular failure represents a critical scenario where maintaining coronary perfusion pressure is paramount. Norepinephrine addresses this by:
- Increasing systemic blood pressure without proportionally increasing pulmonary vascular resistance
- Improving right ventricular perfusion through enhanced coronary perfusion pressure
- Maintaining or increasing cardiac output despite elevated pulmonary pressures
Clinical Evidence Supporting Use
The most compelling evidence comes from chronic PH populations. In patients with chronic pulmonary hypertension experiencing systemic hypotension after anesthesia induction, norepinephrine decreased the pulmonary-to-systemic pressure ratio without changing cardiac index, whereas phenylephrine failed to adequately raise blood pressure in one-third of patients and decreased cardiac output 1. This makes norepinephrine the preferred vasopressor in this setting.
In acute right ventricular failure with pulmonary hypertension, norepinephrine improved cardiac index while progressively reducing pulmonary pressures—the opposite of what might be feared 2. This paradoxical benefit occurs because improved systemic pressure enhances RV coronary perfusion and function.
Neonatal Data Reinforces Mechanism
Studies in newborns with persistent pulmonary hypertension demonstrate that norepinephrine:
- Increased systemic pressure from 33 to 49 mmHg
- Decreased pulmonary/systemic pressure ratio from 0.98 to 0.87
- Improved oxygenation despite unchanged ventilator settings
- Increased pulmonary artery blood flow velocity by 20% 3
Animal models show even more pronounced pulmonary vasodilator effects, with 63% reduction in pulmonary vascular resistance in PH subjects versus 35% in controls 4.
Practical Application
When to Use Norepinephrine in PH:
- Systemic hypotension (systolic BP <100 mmHg or MAP inadequate for perfusion)
- Right ventricular failure with hemodynamic compromise
- Perioperative hypotension in patients with known PH
- Shock states in PAH patients (norepinephrine is among the most commonly used agents) 5
Monitoring Requirements (per FDA label):
- Blood pressure every 2 minutes until target achieved, then every 5 minutes 6
- Use large veins (antecubital preferred; avoid leg veins in elderly or those with vascular disease) 6
- Watch infusion site constantly for extravasation
- Never leave patient unattended during infusion 6
Critical Precautions:
- Extreme caution with MAOIs or tricyclic/imipramine antidepressants (can cause severe, prolonged hypertension) 6
- Avoid during cyclopropane/halothane anesthesia (risk of ventricular arrhythmias) 6
- Contains sulfites—risk of allergic reactions in susceptible patients 6
- Avoid leg veins in elderly due to gangrene risk 6
Comparison to Alternatives
Norepinephrine is superior to phenylephrine in chronic PH because phenylephrine may fail to raise blood pressure adequately and decreases cardiac output without improving the pulmonary-to-systemic pressure ratio 1.
Current practice shows marked variation with 25 distinct vasoactive strategies identified nationally, most commonly combining norepinephrine with vasopressin, phenylephrine, or milrinone 5. This variation reflects clinical equipoise, but the physiologic rationale and available evidence favor norepinephrine as first-line.
Key Pitfall to Avoid
Do not withhold norepinephrine due to fear of worsening pulmonary hypertension. The hemodynamic data consistently shows that in the setting of systemic hypotension with PH, norepinephrine's benefit to RV function through improved coronary perfusion outweighs any theoretical increase in pulmonary vascular resistance. The pulmonary-to-systemic pressure ratio actually improves, which is the critical metric 1, 3.
The primary concern with norepinephrine in PH is not pulmonary vasoconstriction but rather the standard risks of any vasopressor: excessive hypertension, extravasation injury, and drug interactions 6.